You are viewing: China Cancer Biomarkers Market analysis
Part of: Cancer Biomarkers Market (Global)

The China Cancer Biomarkers Market was valued at $1715.7 Million in 2026 and projected to reach to $4215.5 Million by 2031, representing a compound annual growth rate of 16.2%. China's cancer biomarkers market is positioned for exceptional growth through 2031, driven by converging factors including demographic shifts, rising cancer prevalence, and government prioritization of precision medicine.

China Cancer Biomarkers Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Cancer Biomarkers Market Trends and Insights

  • This represents a compound annual growth rate of 16.2%, significantly outpacing global market growth, driven by China's aging population, rising cancer incidence, and substantial investments in precision medicine infrastructure.
  • China's healthcare modernization initiatives and government support for diagnostic innovation are accelerating adoption of advanced biomarker testing across oncology centers and hospitals. The market in China is characterized by increasing demand for early cancer detection and personalized treatment strategies.
  • China's expanding middle class and improved healthcare accessibility are fueling patient demand for biomarker-guided therapies.
  • Between 2026 and 2031, China is expected to emerge as a critical growth engine for the global cancer biomarkers sector, with domestic manufacturers and international players establishing regional hubs to capitalize on the market's rapid expansion and regulatory improvements..

Key Market Statistics

  • CAGR (2026-2031) 16.2% CAGR
  • Market Size, 2026 ~USD 1715.7 Million
  • Forecast, 2031 ~USD 4215.5 Million
  • Country China

China Cancer Biomarkers Market Overview

Rapid Market Expansion :

China's cancer biomarkers market is projected to grow from USD 1,715.7 million in 2026 to USD 4,215.5 million by 2031, representing a 16.2% CAGR that significantly exceeds the global growth rate of 11.6%.

Aging Population Driver :

China's rapidly aging demographic is fueling increased cancer incidence rates, creating sustained demand for advanced biomarker testing and early detection solutions across multiple cancer types.

Precision Medicine Investment :

Substantial government and private sector investments in precision medicine infrastructure are accelerating the adoption of cancer biomarker technologies throughout China's healthcare system.

Healthcare System Modernization :

China's ongoing healthcare reforms and expansion of diagnostic capabilities in both urban and emerging markets are creating unprecedented opportunities for biomarker market penetration.

China Cancer Biomarkers Market Dynamics

  • The 16.2% CAGR reflects strong institutional support for advanced diagnostic infrastructure and increasing healthcare spending.
  • Major cities are establishing comprehensive biomarker testing centers, while rural healthcare expansion initiatives are broadening market reach.
  • Pharmaceutical companies and diagnostic firms are intensifying investments in China-specific biomarker research and localized manufacturing capabilities.
  • The market will likely see consolidation among domestic players and strategic partnerships with international biotech firms seeking to capitalize on this high-growth opportunity..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    In Vitro Diagnostics

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Dna Microarrays
    • Assay Kits
    • Microarrays
    Top Companies
    • ROCHE HOLDINGS AG
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Abbott Laboratories
    • Biomerieux s.a.

      Key Takeaways

      • China's cancer biomarkers market will grow from USD 1,715.7M (2026) to USD 4,215.5M (2031) at a 16.2% CAGR, outpacing global growth.
      • China's aging population and rising cancer prevalence are primary drivers of biomarker adoption and precision oncology expansion.
      • Government support for healthcare modernization and precision medicine in China is accelerating diagnostic innovation and market penetration.
      • China is positioned as a critical growth hub for the global cancer biomarkers market, attracting both domestic and international investment.

      Cancer Biomarkers Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment LUNG CANCER (Cancer Type)
      Forecast Period 2026–2031
      Growth Rate CAGR of 11.6% from 2026 to 2031
      Largest Segment OMICS TECHNOLOGIES (Profiling Technology)
      Market Size Base Year (Billions) ~USD 28.2 (2026)
      Revenue Forecast (Billions) ~USD 48.82 (2031)
      Segments Covered Profiling Technology, Type, Cancer Type, Products

      China Cancer Biomarkers Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Profiling Technology

      • Imaging Technologies
      • Omics Technologies

      By Type

      • 2D Gel Electrophoresis
      • Antibodies
      • Biopsy Instruments
      • Computed Tomography (Ct)
      • Genomics
      • Imaging Instruments
      • Immunoassay
      • In-Situ Hybridization (Ish)
      • Kits And Reagents
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mass Spectrometry
      • Next Generation Sequencing
      • Other Omics Technologies
      • Other Proteomics Technologies
      • Pathology-Based Instrument
      • Polymerase Chain Reaction
      • Positron Emission Tomography (Pet)
      • Probes
      • Protein Microarray
      • Proteomics
      • Ultrasound Imaging

      By Cancer Type

      • Bladder Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Kidney Cancer
      • Leukemia
      • Lung Cancer
      • Melanoma
      • Non-Hodgkin'S Lymphoma
      • Other Cancer Types
      • Prostate Cancer
      • Thyroid Cancer

      By Products

      • Bioinformatics Software
      • Consumables
      • Instruments

      CHINA: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032

      Segment20242025202620272029203020312032CAGR (%)
      BIOPHARMACEUTICAL COMPANIES & CROS437.9499.1576.1666.5899.81052.91238.71457.316.7
      DIAGNOSTIC LABORATORIES1041.71172.31335.71525.42005.82316.12688.63120.715.2
      OTHER END USERS77.684.693.4103.2126.8141.4158.4177.211.3
      RESEARCH AND ACADEMIC INSTITUTES247.9281.1322.9371.7496.9578.5677.2792.816.2
      TOTAL1805.12037.223282666.73529.340894762.85548.115.6

      Target Audience

      • Diagnostic & Biotech Companies : In vitro diagnostics firms and biotech companies need China-specific market data to evaluate expansion opportunities, assess competitive threats, and allocate R&D resources in this high-growth precision medicine market.
      • Pharmaceutical Manufacturers : Pharma companies developing companion diagnostics and targeted therapies require detailed insights into China's biomarker adoption rates, regulatory pathways, and healthcare system integration to support product launches.
      • Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in China's healthcare sector need comprehensive market sizing and growth projections to identify attractive acquisition targets and portfolio companies in cancer diagnostics.
      • Hospital & Clinical Networks : Chinese healthcare institutions and hospital groups need market intelligence on biomarker technologies, vendor landscapes, and reimbursement trends to optimize diagnostic capabilities and clinical outcomes.
      • Government & Policy Makers : Healthcare administrators and policy officials require market analysis to inform precision medicine initiatives, healthcare infrastructure investments, and regulatory frameworks supporting biomarker integration in China.

      Key Companies in the China Cancer Biomarkers Market

      CompanyHQOwnershipStrongest segments
      NANOSTRING TECHNOLOGIES, INCUnited States
      CELL SIGNALING TECHNOLOGY, INC.United States
      TRANSGENOMIC, INC.United States
      SANOFISpain
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging-based biomarker systems and software,In-vitro diagnostics instruments and consumables,Varian oncology platforms and services,
      BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyInstruments (flow cytometers, analyzers, automation),Consumables & reagents (antibodies, kits, collection products, media),
      MYRIAD GENETICSUnited StatesPublic CompanyHereditary cancer and germline oncology tests (e.g., MyRisk, BRACAnalysis CDx),Tumor-based prognostic and companion diagnostics (MyChoice CDx, Prolaris, EndoPredict, Precise Tumor),Other oncology-adjacent genomics and lab services within cancer workflows,
      SYSMEX CORPORATIONJapanPublic CompanyInstruments (hematology, coagulation, cell analysis platforms),Consumables (reagents, calibrators, controls, software-linked services),
      HOLOGIC, INC.United StatesPrivate CompanyBreast cancer imaging systems and software,Biopsy guidance systems and markers,Cytology and related consumables (ThinPrep),

      NANOSTRING TECHNOLOGIES, INC

      NanoString Technologies develops and commercializes molecular analysis platforms for gene expression profiling and genomic research.

      CELL SIGNALING TECHNOLOGY, INC.

      Cell Signaling Technology Inc. produces research antibodies, proteins, and assay kits for cell biology and life sciences research.

      TRANSGENOMIC, INC.

      Transgenomic Inc. provides genetic testing and molecular diagnostics solutions for disease detection and management.

      SANOFI

      Sanofi is a multinational pharmaceutical company developing and marketing medicines, vaccines, and diagnostic products.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a global medical technology company providing diagnostic imaging, laboratory diagnostics, and healthcare IT solutions.

      BECTON, DICKINSON AND COMPANY

      Becton, Dickinson and Company manufactures and distributes medical devices, laboratory equipment, and diagnostic systems.

      MYRIAD GENETICS

      Myriad Genetics is a molecular diagnostics company providing genetic testing and precision medicine solutions for cancer and other diseases.

      SYSMEX CORPORATION

      Sysmex Corporation manufactures and sells hematology, hemostasis, and clinical chemistry diagnostic systems and reagents.

      HOLOGIC, INC.

      Hologic Inc. develops and markets diagnostic and medical imaging systems, particularly for women's health and cancer detection.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise market valuation data for China's cancer biomarkers sector with detailed CAGR projections through 2031, enabling accurate financial forecasting and investment decision-making.
      • Competitive Landscape Intelligence : Understand China-specific market dynamics, key players, and competitive positioning to identify partnership opportunities and market entry strategies in this high-growth region.
      • Regulatory & Infrastructure Insights : Access detailed analysis of China's healthcare policies, precision medicine initiatives, and diagnostic infrastructure development affecting biomarker adoption and commercialization pathways.
      • Demographic & Clinical Trends : Leverage data on China's aging population, cancer incidence patterns, and healthcare spending trends to align product development and market expansion strategies with regional demand drivers.
      • Strategic Market Positioning : Develop evidence-based go-to-market strategies for China by understanding segment opportunities, customer preferences, and growth catalysts specific to this outpacing regional market.

      Frequently asked questions

      What is the projected market size for cancer biomarkers in China by 2031?

      China's cancer biomarkers market is projected to reach USD 4,215.5 million by 2031, growing from USD 1,715.7 million in 2026.

      What is the CAGR for China's cancer biomarkers market?

      China's cancer biomarkers market is expected to grow at a compound annual growth rate of 16.2% between 2026 and 2031.

      What factors are driving growth in China's cancer biomarkers market?

      Key drivers include China's aging population, rising cancer incidence, government healthcare modernization initiatives, and increased investment in precision medicine infrastructure.

      How does China's market growth compare to global trends?

      China's 16.2% CAGR significantly exceeds the global cancer biomarkers market CAGR of 11.6%, positioning China as a high-growth region.

      What role does China play in the Asia Pacific cancer biomarkers market?

      China is the largest and fastest-growing market within Asia Pacific, serving as a critical growth engine for regional and global biomarker adoption.

      RESEARCH METHODOLOGY

      The objective of the study is to analyze key market dynamics, including drivers, opportunities, restraints, challenges, and key players' strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, the competitive landscape of the cancer biomarkers market will be analyzed, and market players will be evaluated on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.
      The four steps involved in estimating the market size are

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess prospects.

      The following is a breakdown of the primary respondents

      Cancer Biomarkers Market Size, and Share

      Note 1: Others include sales, marketing, and product managers.
      Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

      COMPANY NAME

      DESIGNATION

      Thermo Fisher (US)

      Sales Manager

      F. Hoffmann-La Roche AG (Switzerland)

      Product Manager

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total market size of cancer biomarkers. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry have been identified through extensive secondary research
      • The revenues generated by leading players operating in the cancer biomarkers market have been determined through primary and secondary research
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

      Cancer Biomarkers Market : Top-Down and Bottom-Up Approach

      Cancer Biomarkers Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the overall market size using the process described above, the total market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Cancer biomarkers are biological molecules produced by the body or a tumor in a person with cancer. Cancer biomarker testing helps differentiate alterations in the tumor. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. It can also be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. Biomarkers can be DNA, RNA, proteins, or metabolomic profiles specific to the tumor. They enhance cancer detection and facilitate high-speed, noninvasive diagnosis using profiling technologies such as omics, imaging, immunoassays, and cytogenetics.

      Key Stakeholders

      • Product Manufacturers, Distributors, and Suppliers
      • Diagnostic Laboratories
      • Research Laboratories and CROs
      • Ambulatory Testing Centers
      • Contract Testing Laboratories
      • Academic Universities and Medical Research Centers
      • Research and Development (R&D) Centers

      Report Objectives

      • To define, segment, and forecast the cancer biomarkers market by profiling technology, cancer type, product, application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to six regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries
      • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To benchmark players within the market using the proprietary company evaluation matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
      • To study the impact of AI on the market, along with the macroeconomic outlook for each region

      Available customizations:

      MarketsandMarkets offers the following customizations for this market report.

      Product Analysis

      • Product matrix, which provides a detailed comparison of the product portfolio of each company in the cancer biomarkers market

      Country Information

      • Additional country-level analysis of the cancer biomarkers market

      Company Profiles

      • Additional five company profiles of players operating in the cancer biomarkers market.

      Get the Full Cancer Biomarkers Market Report

      Full forecast, segment splits, and company analysis for all Cancer Biomarkers Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status